Key result
In vitro treatment with clopidogrel significantly reduced platelet aggregation and fibrinogen expression in both groups, and decreased P-selectin, phosphatidylserine, and malondialdehyde only in hyperlipidemic platelets.
Why the study?
Does in vitro clopidogrel alter platelet aggregation and biomarker expression in platelets from healthy and hyperlipidemic subjects?
Does in vitro clopidogrel alter platelet aggregation and biomarker expression in platelets from healthy and hyperlipidemic subjects?
In vitro clopidogrel demonstrates novel antiplatelet effects, particularly in hyperlipidemic subjects, by modulating various platelet biomarkers.
In vitro findings from this animal model are hypothesis-generating; prospective human studies needed before clinical consideration.
OBJECTIVE: We aimed to detect novel in vitro effects of clopidogrel on platelets by assessment of the following parameters: malondialdehyde, glutathione, nitrite, aggregation response, and expressions of P-selectin, fibrinogen, apolipoprotein A1, apolipoprotein B, and phosphatidylserine. METHODS: Platelets were obtained from healthy (n: 9) and hyperlipidemic (n: 9) volunteers. Expressions of P-selectin, fibrinogen, apolipoproteins A1/B and phosphatidylserine with and without clopidogrel were assayed by flow cytometry. Malondialdehyde, glutathione, aggregation and nitrite levels were also assayed. RESULTS: Without clopidogrel, the baseline values of platelet aggregation, malondialdehyde, and expressions of P-selectin, fibrinogen and phosphatidylserine were significantly higher, whereas nitrite and expression of apolipoproteins A1/B were significantly lower in hyperlipidemics than in the healthy group. In both groups, clopidogrel significantly reduced aggregation and expression of fibrinogen, but it elevated nitrite levels. Clopidogrel significantly decreased P-selectin and phosphatidylserine expression and malondialdehyde but increased expressions of apolipoproteins A1/B only in hyperlipidemics. CONCLUSION: It seems that clopidogrel has some new in vitro antiplatelet effects. The present study is a basic in vitro study to suggest new insights into the effects of clopidogrel on platelet functions.
No takes yet. Share an insight, caveat, or question.
Özsavcı et al. (2010) studied Hyperlipidemia (n=18). Clopidogrel vs. Without clopidogrel (baseline) was evaluated on Platelet aggregation, malondialdehyde, glutathione, nitrite, and expressions of P-selectin, fibrinogen, apolipoprotein A1/B, and phosphatidylserine. In vitro treatment with clopidogrel significantly reduced platelet aggregation and fibrinogen expression in both groups, and decreased P-selectin, phosphatidylserine, and malondialdehyde only in hyperlipidemic platelets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: